期刊
BLOOD
卷 123, 期 22, 页码 3478-3487出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2013-11-537704
关键词
-
类别
资金
- Ministry of Health [RC41/08, RC 01/09]
- Ministry of University [PRIN MFXE7L_004]
- Fondazione Casali
- Ricerca Corrente Target molecolari della APS [22-07-2010]
- Istituto di Ricovero e Cura a Carattere Scientifico Istituto Auxologico Italiano, Milan, Italy
A single-chain fragment variable(scFv) recognizing beta 2-glycoprotein 1 (beta 2GPI) from humans and other species was isolated from a human phage display library and engineered to contain an IgG1 hinge-CH2-CH3 domain. The scFv-Fc directed against beta 2GPI domain I-induced thrombosis and fetal loss, thus mimicking the effect of antibodies from patients with antiphospholipid syndrome (APS). Complement is involved in the biological effect of anti-beta 2GPI scFv-Fc, as demonstrated by its ability to promote in vitro and in vivo complement deposition and the failure to induce vascular thrombosis in C6-deficient rats and fetal loss in C5-depletedmice. A critical role for complement was also supported by the inability of the CH2-deleted scFv-Fc to cause vessel occlusion and pregnancy failure. This antibody prevented the pathological effects of anti-beta 2GPI antibodies from APS patients and displaced beta 2GPI-bound patient antibodies. The CH2-deleted antibody represents an innovative approach potentially useful to treat APS patients refractory to standard therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据